Exeget (XGN) Q2 2025: Per-Territory Revenue Climbs 50%, Commercial Leverage Accelerates
Exeget’s Q2 saw record revenue and a 50% jump in average per-territory sales, signaling deepening commercial leverage and operational discipline. The company’s organic growth stems from clinical adoption of novel biomarkers and a revitalized salesforce, with expansion tailwinds set to materialize in late 2025. Management’s posture is increasingly confident, underpinned by a strengthened balance sheet and a robust pipeline, but investors should track ASP realization and execution on market access as the next phase unfolds.
Summary
- Commercial Leverage Surges: Revenue per territory up over 50% since 2023, reflecting strong field execution.
- Biomarker Innovation Drives Adoption: New T-cell and RA markers are accelerating clinical uptake and physician engagement.
- Profitability in Sight: Operating cash flow nears breakeven, with positive adjusted EBITDA targeted by year-end.
Performance Analysis
Exeget delivered a record quarter, with Q2 revenue rising 14% year-over-year and sequential growth driven by both increased test volume and average selling price (ASP) expansion. The core Advise CTD autoimmune diagnostics platform, which identifies connective tissue diseases, saw its best volume since strategic restructuring in 2023, confirming traction from both existing and new physician customers. Notably, revenue per territory reached $430,000, up from $285,000 two years ago, a direct result of commercial process improvements and field team stability.
Gross margin improved to just over 60%, aided by ASP gains and operational normalization following Q1 lab investments. Operating expenses rose to $13 million, reflecting R&D investments and leadership hires, but management expects these to flatten as a percentage of revenue, supporting operating leverage. Net loss widened due to non-cash debt-related charges, but adjusted EBITDA loss remained stable, and the company is approaching free cash flow neutrality. The balance sheet was fortified by a $20 million equity raise and new credit capacity, providing flexibility for commercial and R&D investment.
- Organic Growth Momentum: Volume grew 7% YoY, with gains attributed to existing team execution and new biomarker adoption, not yet reflecting salesforce expansion.
- ASP Expansion Moderates: Trailing 12-month ASP rose by $27 to $428, with management taking a conservative accrual approach to new markers.
- R&D and Pipeline Spend: Elevated operating expenses reflect strategic investment in new biomarkers and leadership, positioning for future launches.
Exeget’s financial trajectory is increasingly underpinned by multi-pronged growth levers—volume, ASP, and pipeline progress—though realization of full ASP potential and market access wins remain key to sustaining momentum into 2026.
Executive Commentary
"What's especially encouraging is that this growth is being driven organically by our existing commercial team and the growing clinical recognition of our differentiated science. Our biomarker launch this past January continues to go extremely well. The addition of novel T-cell and RA markers has been a meaningful catalyst in our commercial conversations."
John Abali, President and CEO
"Our balance sheet now provides us with the flexibility to invest in growth while maintaining a clear path to positive operating cash flow. Gross margin in the second quarter was just over 60 percent, up from about 59 percent in the first quarter. We expect continued gross margin expansion throughout the year, driven mostly by our expected ASP improvements."
Jeff, CFO
Strategic Positioning
1. Commercial Execution and Territory Expansion
Exeget’s commercial engine is showing marked improvement, with average revenue per territory up 50% since 2023, reflecting both field team stability and improved sales processes. The company is methodically expanding territories, with 42 at quarter-end and a line of sight to 44-45 by year-end, but is avoiding overextension by scaling empirically based on local demand metrics.
2. Differentiated Biomarker Portfolio
Innovation in autoimmune diagnostics is Exeget’s core moat. The January launch of new T-cell and seronegative RA markers has driven clinical adoption and given the salesforce new engagement levers. The upcoming launch of anti-PAD4 antibodies targets further penetration in rheumatoid arthritis, with management expecting additional, albeit smaller, ASP tailwinds.
3. R&D Pipeline and Biopharma Partnerships
The pipeline spans urine and blood-based lupus nephritis diagnostics, with validation partnerships through the NIH and pharma collaborations. The biopharma business, though lumpy, is margin accretive and expected to contribute more meaningfully in the back half of the year as novel biomarkers attract new pharma programs.
4. Market Access and ASP Realization
ASP expansion remains the most sensitive lever for margin and profit improvement. The company’s blended ASP of $428 remains well below the $1,299 clinical lab fee schedule, leaving substantial room for payer wins and revenue cycle optimization. Management is focused on appeals, payer negotiations, and medical director engagement to drive further ASP gains over time.
5. Disciplined Capital Allocation
Recent capital raise and debt refinancing provide Exeget with over $40 million in liquidity and $50 million in additional credit capacity, enabling opportunistic investment in both commercial and scientific growth without compromising the path to profitability.
Key Considerations
Exeget’s Q2 performance is a reflection of both commercial discipline and scientific innovation, but forward execution will hinge on realizing the full impact of expansion levers and sustaining margin improvement as the business scales.
Key Considerations:
- Salesforce Expansion Lag: New territories added in Q2 have not yet contributed to volume, with impact expected in late 2025 and into 2026.
- ASP Sensitivity: Conservative accrual rates on new biomarkers delayed some ASP benefit to future quarters, but management remains bullish on achieving a $90 uplift over time.
- R&D Investment Payoff: Significant pipeline investment will require successful payer reimbursement and clinical adoption, particularly in lupus nephritis and kidney damage diagnostics.
- Market Access Progress: Wins with payers like TRICARE and regional plans are encouraging, but national coverage remains a long-term process requiring persistent engagement.
Risks
Key risks include ASP realization lag, payer pushback, and the inherent lumpiness of biopharma revenue, which could disrupt near-term margin and cash flow improvement. Seasonality in testing volumes and execution challenges in scaling new territories also present headwinds, and any delays in pipeline commercialization or reimbursement could impact long-term growth targets.
Forward Outlook
For Q3 and Q4, Exeget expects:
- Continued volume and ASP growth, with salesforce expansion impact building into Q4
- Gross margin improvement as higher ASPs and operational leverage take hold
For full-year 2025, management maintained guidance:
- Revenue of $65 to $70 million, with positive adjusted EBITDA targeted at the high end of the range in Q4
Management cited multiple levers for growth, including further territory additions, new biomarker launches, and expanding biopharma partnerships, while emphasizing discipline in expense management and capital allocation.
- Salesforce expansion impact will lag, but is expected to accelerate growth in late 2025
- ASP improvement remains a core focus, with payer wins and revenue cycle optimization as key drivers
Takeaways
Exeget’s Q2 underscores a business reaching commercial inflection, with record per-territory revenue and operational leverage setting the stage for profitability. The next phase will require execution on market access, pipeline launches, and sustained field performance as new territories ramp.
- Commercial Leverage: Core business is scaling efficiently, with existing team driving outsized gains ahead of territory expansion impact.
- Innovation Pipeline: New biomarkers are differentiating Exeget in a stagnant field, but payer adoption and reimbursement are gating factors for full value realization.
- Execution Watch: Investors should monitor ASP realization, contribution from new territories, and pipeline progress as the company transitions toward sustainable profitability.
Conclusion
Exeget’s Q2 marked a step-change in commercial execution and operational discipline, with organic growth and innovation reinforcing its leadership in autoimmune diagnostics. The company’s trajectory is positive, but the next leg will depend on execution in market access, salesforce ramp, and pipeline conversion.
Industry Read-Through
Exeget’s results highlight the untapped potential for innovation in autoimmune diagnostics, where legacy testing has dominated for decades. The traction with novel biomarkers and consultative field engagement signals a broader industry shift toward precision medicine and payer-driven value capture. Competitors in diagnostics and life sciences tools should note the importance of commercial discipline, payer engagement, and R&D pipeline validation as key differentiators in a market increasingly focused on clinical utility and cost-effectiveness. The lumpy but accretive biopharma revenue stream also illustrates the growing interplay between diagnostics and drug development, a trend likely to accelerate as new modalities enter the autoimmune space.